



Pharmacy and Therapeutics (P&T) Committee Meeting
December 13, 2016
6:00 PM – 8:00 PM
MINUTES

P&T Committee Members

Matthew Flynn, MD
Randy Grigg, MD
John Anderson, MD
Jennifer Burch, PharmD
Michael Spiritos, MD
John Engemann, MD
David Konanc, MD
Steven Bentsen, MD (Beacon HealthOptions)
Connie Rominger (BCBSNC)
Patti Forest, MD (State Health Plan)
Jamilah Brunson, PharmD (State Health Plan)
Lotta Crabtree, JD (State Health Plan) Interim Chair

State Health Plan (SHP) Staff

Natasha Davis
Neha Zadoo
Jennifer Gontarz
Lucy Barreto

SHP Contracted Vendors

H. Renee Jarnigan, RPh (CVS Health)
Robbie Wallace (CVS Health)

Guests

Mark Roshelli, Sanofi US

I. Welcome, Introductions and Conflict of Interest

Jamilah Brunson welcomed the committee members and guests.

II. Minutes from August 9, 2016 Meeting

The committee members reviewed and approved the August 9, 2016 minutes.

III. SHP Update

Jamilah shared information pertaining to the State Health Plan's ***Proposed 2017 Pharmacy Formulary and Benefit Design Changes*** relative to closed formulary drugs. The Board of Trustees approved the closed formulary in June, however, Lotta noted that statutes require the review and approval of formulary restrictions by the P & T committee.

Jamilah briefly referred to the formulary exception process that was distributed in the packet upon arrival. At the previous P&T meeting, this was completely addressed, therefore the State Health Plan provided mainly for reference.

Jamilah reviewed the physician FAX form in the packet that will be used for formulary exceptions. It was stated that an urgent review would be handled within 24 hours and non-urgent requests are handled within 72 hours by a coverage determination group at the PBM. Some physicians expressed concern if the coverage was denied, but the appeals process was offered.

Dr. Konanc and Dr. Grigg expressed concern with the administrative tasks associated with getting a drug approved, and weighing out the costs of personnel vs. savings to the SHP. Lotta Crabtree explained that choosing the closed formulary, with the given population, SHP stands to save \$400-\$500 million over three years, by CVS estimates. Jamilah added that the purpose of the P&T committee is to provide a forum to vet out any issues with drug coverage/exclusions.

Jamilah reviewed all drugs on the list by therapeutic class, engaging all members present for comments. The specific classes are listed below, to include the drugs under review.

Program Review of Non-Covered Drugs for 2017

Anti-infective class changes: Doryx, Nuessa

Anti-viral class changes: Valcyte, Daklinza, Olysio, Zepatier, Viekira, Viekira XR, Technivie, Valtrex

Biologic class changes: Cuvitru, Pegasys, Extavia, Plegridy, Avonex, Kineret, Prolia, Otezla, Xeljanz, Zeljanx XR, Actemra, Orencia, Remicade, Cimzia, Simponi, Cosentyx

Cardiology class changes: EpiSnap Kit, Adrenaclick, Lescol XL, Liptruzet, Livalo, Matzim LA, Plavix, Teveten HCT, Lipitor, Norvasc, Praluent, QBRELIS, Pradaxa, Teveten, Edarbi, Byvalson, Atacand HCT, Edarbyclo, Exforge, Exforge HCT, Atacand, Diovan, Durlaza, Cardizem, Cardizem CD, Cardizem LA, Crestor, Tricor, Tyvaso, Ventavis, Adcirca, Revation, Remodulin, Advicor, Altoprev, Diovan HCT, Savaysa, Dutoprol, Opsumit, Prestalia

CNS class changes: Namzaric, Adzensys XR, Evekeo, Quillichew ER, Adderall XR, Fanatrex, Spritam, Khedezla, Oleptro, Cymbalta, venlafaxine ext-rel tabs (except 225 mg.), Rytary, Intuniv, Invega Trinz, Vraylar, Abilify, EXONDYS 51, Belsomra, Intermezzo, Lunesta, Rozerem, Onzetra Xsail, Amrix, Arthrotec, Fenortho, Naprelan, Tivorbex, Vivlodex, Lomaira, Qsymia, Lazanda, Zubsolv, Oxaydo, Xtampza,

Probuphine, Emend, Yosprala, Xenazine, Allzital, butalbital/APA/Caffeine capsules, Fioricet, Abstral, Embeda, Elavil 25mg tablets, Evzio

Dermatology class changes: Alcortin A, Aloquin, Pennsaid, Noritate, Carac, flurouracil cream 0.5%, Tolak, Apexicon E, clobetasol propionate 0.05% spray, Clobex, Olux-E, Sernivo, Ultravate, Denavir, Novacort, Urevaz, Aczone 7.5% gel, Avar AER 9.5-5%, Avar LS AER 10-2%, ASTERO

Diabetes class changes: Invokana, Invokamet, Kazano, Kombiglyze XR, Nesina, Onglyza, Oseni, Riomet, Lantus, Fortamet, Glumetza, Invokamet XR, Glyxambi, non-BD needles and syringes, Non-One Touch Ultra/Verio Test strips, Actos, Bydureon, Byetta, Humalog, Humalog 50/50, Humalog 75/25, Humulin 70/30, Humulin N, Humulin R, Apidra, Afrezza, Synjardy, Toujeo

Endocrine class changes: Cetylev, Androgel, Fortesta, Testim, testosterone gel 1%, Vogelxo, Bravelle, Gonal-F, Repronex, Millipred, Rayos, Zurampic, Genotropin, Norditropin, Nutropin AQ, Omnitrope, SAizen, Zomactan, RElistor, Makena, DexPak, Natesto

Gastrointestinal class changes: Asacol HD, Delzicol, Gialax Kit, Zegerid, Prevacid, Protonix, Nexium capsule, Nexium granules, omeprazole-sod bicarb capsules

Genitourinary class changes: Jalyn, Oxytrol, Detrol LA, Enablex, Toviaz, Gelnique

Hematologic class changes: Procrit, Idelvion, Adynovate, Afstyla, Vonvendi, Amicar, Ferriprox, Neupogen, Helixate FS

Immunosuppressive class changes: Envarsus XR

Nephrology class changes: Fosrenol, Keveyis

Nutrition class changes: Carnitor, Elfolate, Enbrace HR

Oncology class changes: Farydak, Evomela, Tasigna, Odomzo, Cotellic, Xtandi, Cabometyx, Alecensa, Gleevec, Nilandron

Ophthalmic class changes: Lastacraft, Lumigan

Osteoarthritis class changes: Euflexxa, Gelsyn-3, Genvisc, Hymovis, Monovisc, Orthovisc, Synvisc, Synvisc-One

Otic class changes: Floxin, Otiprio, Otovel

Respiratory class changes: Obredon, Beconase AQ, Nasonex, Omnaris, Qnasl, Rhinocort Aqua, Ticanase, Ticaspray Pak, Veramyst, Zetonna, Incruse Ellipta, Proventil HFA, Aerospan, Alvesco, Ventolin HFA, Xoponex HFA, Seebri, Tudorza Pressair, Utibron Neohaler, Stiolto Respimat, Symbicort, Cinqair, Tobi, Tobi Podhaler

Various committee members had expressed concerns over the following drugs to be removed from coverage:

Belsomra (suvorexant): Dr. Konanc expressed concern about the non-formulary status citing the unique mechanism of action in comparison to the formulary alternatives. He request member (utilization) impact be considered.

Oleptro (trazadone ext rel tab): Dr. Grigg expressed concern citing issues with somnolence for patients requiring high doses for the depression indication; immediate release formulation is sufficient for those utilizing the agent for sleep, not depression.

Farydak (panobinostat): Dr. Spiritos concerned there is no formulary alternative or “me too” drug on the market for this drug.

Tasigna: P&T raised concern that this is a first-line agent with data in the literature that supports its superiority in this class. CVS must provide rationale; SHP to provide utilization.

Alecensa (alectinib): This drug is preferred for patients with NSCLC with brain metastasis and the guideline recommends for patients with ALK positive mutation that has failed Xalkori (crizotinib).

Cabometyx (cabozantinib): P&T does not recommend exclusion – wants rationale and member utilization.

All voted in favor of the exclusions with the exception of further review of the above six drugs in the coming months. The committee agreed that the final decision for exclusion or inclusion in the formulary would be made by the Plan’s Executive Administrator. In the meantime, providers can use the exception process for these drugs when appropriate.

Following the meeting, the Plan reached out to Dr. Shanahan for comments on the following drug exclusions and is waiting for response: Kineret, Otezla, Xeljanz and Xeljanz XR, Actemra, Orencia, Remicade, Cimzia, Simponi and Cosentyx.

I. Other Topics

Dr. Flynn asked for a mobile app version of the formulary and drugs requiring prior authorization. Dr. Konanc added that the ability to interface with EMR at the point of care would be helpful as well. Robby Wallace from CVS agreed to look into this topic to see how CVS could support provider tools through the Surescripts network. Electronic prior authorization is available through CoverMyMeds. More information can be shared at the next P&T meeting.

The next P&T Committee meeting will be held on Tuesday, February 21, 2017.